Hepatitis E News and Research

RSS

Hepatitis E is a viral hepatitis (liver inflammation) caused by infection with a virus called hepatitis E virus (HEV).

World's first urine-based tuberculosis diagnostics tool

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostics systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, in a new video today unveiled the world's first urine-based tuberculosis diagnostics tool.

9 May 2011

Innovative detection practices may prevent liver diseases

Research being presented at Digestive Disease Week- shows that screening individuals for hepatitis C based on age instead of conventional risk factors may help increase detection rates as well as prevent liver disease.

9 May 2011

Parasites in human waste fertilizers alarm health experts

It has been suggested that human faeces used as fertiliser on farms are leading to the spread of ‘Third World’ parasites causing a serious stomach illness across Sydney.

8 May 2011

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has published an article in its current issue entitled, "Electroporation Delivery of DNA Vaccines: Prospects for Success."

7 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

AGA honors four young gastroenterologists with prestigious Research Scholar Awards

The American Gastroenterological Association Research Foundation has announced its 2011 research scholars. The grants have been awarded to four outstanding young gastroenterologists who promise to make significant strides in the field of gastrointestinal research.

6 May 2011

New study: Text-heavy labels can reduce acetaminophen overdose

While well known for relieving everyday aches and pains, few realize that when misused, acetaminophen can lead to acute liver failure and even death, often due to accidental overdose by an uninformed consumer. A new small study looked at what's missing in consumer education about acetaminophen and how to overcome those gaps.

3 May 2011

New antioxidant may prevent liver damage in chronic alcoholics

An antioxidant may prevent damage to the liver caused by excessive alcohol, according to new research from the University of Alabama at Birmingham.

3 May 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.

30 Apr 2011

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb Company today announced first quarter results that included strong sales and earnings growth, and several key R&D milestones—most notably U.S. regulatory approval for YERVOY. The company also confirmed guidance for the year.

30 Apr 2011

Neither vitamin E nor metformin reduces liver enzymes in children with fatty liver disease: Study

The largest study of its type has found that neither vitamin E, which is an antioxidant, nor the diabetes drug metformin, successfully reduced liver enzymes in nonalcoholic fatty liver disease in children or teens, according to a paper published in the April 27, 2011 issue of Journal of the American Medical Association.

30 Apr 2011

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

Vertex Pharmaceuticals Incorporated announced that the Antiviral Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously to recommend FDA approval of telaprevir for people with genotype 1 chronic hepatitis C.

29 Apr 2011

Hepatitis B virus rebound common in patients receiving nucleoside analogs for chronic hepatitis B

A rebound of the Hepatitis B virus is common in patients receiving nucleoside analogs for chronic hepatitis B, according to a study from U-M hepatologists. But nearly 40% of the rebounds or virological breakthroughs (VBTs) were not related to antiviral drug resistance.

28 Apr 2011

Panel speakers to discuss hepatitis C prevention, treatment at Mayes College event

Mayes College of Healthcare Business and Policy at University of the Sciences is hosting a panel discussion on hepatitis C prevention and treatment, on Thursday, April 28, 2011, from 5 to 7 p.m.

28 Apr 2011

IL28B gene plays a key role in spontaneous HCV clearance in infants

New research shows that high maternal viral load and co-infection with human immunodeficiency virus are the only risk factors associated with vertical transmission of the hepatitis C virus.

28 Apr 2011

FDA Advisory Committee recommends approval of Merck's VICTRELIS for chronic HCV genotype 1 infection

Merck announced today that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted unanimously that the available data support approval of Merck's investigational medicine VICTRELIS™ (boceprevir) for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infection in combination with current standard therapy.

28 Apr 2011

Biomagnetics accepts Los Alamos National Labs' optical biosensor for disease diagnosis

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has accepted delivery of the world's first integrated optical biosensor for disease diagnosis.

27 Apr 2011

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that enrollment has commenced at North American sites in its pivotal Phase 3 clinical trial program for BI 201335, the Company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).

27 Apr 2011

FDA supports new Hepatitis C drug from Vertex Pharmaceuticals

Vertex pharmaceuticals jumped 10 percent in value on the Nasdaq after U.S. regulators FDA said the company’s experimental hepatitis C drug cures more patients than current therapies.

26 Apr 2011

Study: HIV infection linked to increased risk of heart failure

Patients with HIV infection without a prior history of coronary heart disease may be at a higher risk of developing heart failure, according to a report in the April 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

26 Apr 2011

Hepatitis E News and Research

Further Reading

World's first urine-based tuberculosis diagnostics tool

Innovative detection practices may prevent liver diseases

Parasites in human waste fertilizers alarm health experts

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

AGA honors four young gastroenterologists with prestigious Research Scholar Awards

New study: Text-heavy labels can reduce acetaminophen overdose

New antioxidant may prevent liver damage in chronic alcoholics

Merck first quarter sales increase 1% to $11.6 billion for 2011

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Neither vitamin E nor metformin reduces liver enzymes in children with fatty liver disease: Study

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

Hepatitis B virus rebound common in patients receiving nucleoside analogs for chronic hepatitis B

Panel speakers to discuss hepatitis C prevention, treatment at Mayes College event

IL28B gene plays a key role in spontaneous HCV clearance in infants

FDA Advisory Committee recommends approval of Merck's VICTRELIS for chronic HCV genotype 1 infection

Biomagnetics accepts Los Alamos National Labs' optical biosensor for disease diagnosis

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

FDA supports new Hepatitis C drug from Vertex Pharmaceuticals

Study: HIV infection linked to increased risk of heart failure

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News